Board Of Directors
Executive Partner and Founder
Chairman of the Board
Mike has 28 years of operating and management experience, most recently at Quintiles an Executive Vice President. In this role, Mike was responsible for Quintiles’ global operations in Health Engagement and Communications, Legal and Risk Management, Real Estate and Facilities, Human Resources as well as Security. He was also the Chairman of the company’s European, Middle East, Africa and Latin American management board, in which he was accountable for the organic and inorganic growth strategies of the regions. Mike joined Quintiles in July of 2003 following 10 years at Charles Schwab Corp., where he was Senior Vice President of Human Resources for the company’s global retail and internet organisations. Mike sits on the boards of Oxford Cancer Biomarkers Ltd., HUYA Bioscience International and the Multiple Myeloma Research Foundation. He holds a bachelor’s degree in Behavioural Sciences from The Ohio State University.
Lori Tauber Marcus
Vice Chairman of the Board
Lori Marcus is an independent board director and keynote speaker. She is currently serving in the role of Vice Chairman of the MMRF board. Lori is also the Chairman of the board of DNA Diagnostics Center, a growing leader in private DNA testing services, where she guides overall strategy and governance for corporate growth. Additionally, she is an independent Board Director for SHARE, a 40-year-old survivor-led organization based in New York City that provides support, information, and resources to women affected by breast and ovarian cancers. Lori also currently serves on the CMO advisory board for VentureBeat and is a board advisor to Carrington Farms.
Most recently, Ms. Marcus served as Interim Global Chief Marketing Officer for Peloton Interactive, Inc., a private equity and venture capital backed home fitness innovator, At Peloton, Lori drove business growth with strategy, brand marketing, communications, PR, social/digital media, consumer insights, data analytics, creative services, and community engagement. Prior, Lori was Chief Global Brand and Product Officer at Keurig Green Mountain. With more than 30 years of broad-based marketing and general management experience, Lori was responsible for global brand and product management for the Keurig system of innovative brewers and beverages. During her tenure at Keurig Green Mountain, she also led the company’s global marketing efforts and all aspects of e-commerce, digital/social media, marketing insights, and graphic design. Lori was also formerly Chief Marketing Officer of The Children’s Place Retail Stores and SVP Marketing at PepsiCo.
Lori is a graduate of the Wharton School, University of Pennsylvania.
MMRF and MMRC
Henry and Allison McCance Family Senior Fellow of Business Administration
Faculty Co-Chair, HBS Kraft Precision Medicine Accelerator
Harvard Business School
Kathy Giusti, a multiple myeloma patient, is the Founder of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). She is the Henry & Allison McCance Family Senior Fellow at Harvard Business School, where she serves as Faculty Co-Chair of HBS Kraft Precision Medicine Accelerator, a $20M program endowed by Robert Kraft and the Kraft Family Foundation. She currently serves on the MMRF Board of Directors. Giusti has more than two decades of experience in the pharmaceutical industry, previously holding senior positions at G.D. Searle and Merck.
Since founding the MMRF in 1998, Giusti has become a widely respected leader in establishing innovative, collaborative research models in the areas of tissue banking, genomics, and clinical trials. These models are dramatically accelerating the pace at which lifesaving treatments are brought to patients and are building an end-to-end solution in precision medicine. Today, Giusti is recognized as a pioneer of precision medicine, a champion of open-access data sharing, and a strong advocate for patient engagement.
In 2016, Giusti was named Faculty Co-Chair of the Harvard Business School (HBS) Kraft Precision Medicine Accelerator. Under Giusti’s leadership, the HBS Kraft Precision Medicine Accelerator convenes best-in-class leaders from science, business and technology to identify and solve challenges slowing the advancement of precision medicine. The HBS Kraft PM Accelerator disseminates best practices and models to overcome these challenges, and, ultimately, enables faster adoption of high-impact innovations.
Giusti’s has earned several prestigious awards and recognitions, including being named 1 of 3 Top Business Leaders Disrupting Medicine by Fortune Magazine and #19 on Fortune’s World’s 50 Greatest Leaders list. Giusti was also named one of the world’s 100 Most Influential People by TIME magazine. In 2017, she received PRIMO’s Exceptional Women in Oncology award. In addition, she received the Open Science Champion of Change award by the White House and has been honored with the American Association for Cancer Research Centennial Medal for Distinguished Public Service and the Healthcare Businesswomen’s Association’s Woman of the Year Award.
Giusti served on President Obama’s 2015 Precision Medicine Initiative Working Group and continues to act as an active advisor to the Obama PMI (“All of Us”) and Vice President Biden’s Cancer Moonshot program. She currently is a member of the Harvard Business School (HBS) Health Advisory Board and has previously served on the President’s Council of Advisors on Science and Technology (PCAST), National Cancer Advisory Board (NCAB), and the National Cancer Policy Board (NCBP).
Giusti has been featured on the Today Show, NBC Nightly News, CBS Evening News, Fox News, CNN, and Bloomberg. Her efforts have also been profiled by Fortune, The Wall Street Journal, Harvard Business Review, The New York Times, Forbes, The New Yorker, WIRED, and Fast Company.
Giusti received her MBA in general management from Harvard Business School. She holds an honorary Doctorate from the University of Vermont.
Kenneth Anderson, MD
Jerome Lipper Multiple Myeloma Center,
Dana-Farber Cancer Institute
Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom’s Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment and is a Doris Duke Distinguished Clinical Research Scientist. In addition to serving on the Board of Directors of the MMRF, Dr. Anderson serves as Chairman of the MMRF’s Scientific Advisory Committee, Chairman of the Multiple Myeloma Research Consortium, and Chairman of the National Comprehensive Cancer Network’s Multiple Myeloma Clinical Practice Guidelines Committee.
Karen E. Andrews
Senior Vice President and General Counsel
March of Dimes
Karen E. Andrews is currently SVP and General Counsel for the March of Dimes. Previously Karen was the General Counsel and Corporate Secretary of BBDO Worldwide, Inc. where she was responsible for the management of the legal activities of over 150 individual operating units throughout the world. Prior to joining BBDO Worldwide, Ms. Andrews was Associate General Counsel and Director of Television Business Affairs at Time Inc. Ms. Andrews began her career in law as a Litigation Associate at the New York law firm of Weil, Gotshal & Manges where she specialized in Entertainment Litigation. Ms. Andrews graduated cum laude from the University of Vermont with a Bachelor of Science degree in biology and earned her law degree, cum laude, from Temple School of Law. Ms. Andrews is a member of the American Bar Association and the New York State Bar Association. In 1998, Ms. Andrews co-founded the Multiple Myeloma Research Foundation with Kathy Giusti.
Tom was appointed President of SAC Capital in July 2008. He joined SAC in October 1999 as Chief Operating Officer. Prior to joining SAC, Tom was President of Investment Management Services, Inc (“IMS”) from 1996 to 1999. He joined Moore Capital /IMS in 1993 and served as its Director of Trading Operations and then Vice President until IMS split off from Moore in 1995. Tom joined Moore Capital /IMS from Goldman Sachs Trust Company, where he was a Vice President with responsibilities for daily operations, technology, and client services. From 1986 to 1993, Tom was in the operations and equity divisions of Goldman, Sachs & Co., becoming Vice President in 1991. He retired from SAC December 2014.
President and Chief Executive Officer
MMRF and MMRC
Paul Giusti was recently appointed as the President & Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF), a world-renowned cancer-research organization. Prior to the MMRF, Mr. Giusti worked as a Chief Executive Officer, leader, executive and entrepreneur for over 30 years; he has founded, managed and led a variety of businesses throughout his career.
Most recently, Mr. Giusti served as the Chief Executive Officer of Structural Graphics, an integrated marketing firm. Mr. Giusti led the turnaround and repositioning of the firm, including the launching of a growing online product offering. Mr. Giusti now serves as Chairman of the Structural Graphics’ Board of Directors.
Mr. Giusti is also a Co-Founder and Partner in Halen Homes, a privately-held home building and real estate development company. He is also the Co-Founder and Managing Member of a real estate investment firm.
Early in his career, Mr. Giusti worked for several years as an executive for Fairfield, Connecticut-based GE where he held a number of management positions with a wide range of responsibilities.
Mr. Giusti has worked closely with the MMRF since its founding in 1998. In addition to chairing the current $100 million capital campaign, he has served as a consultant for a number of foundation projects, led several MMRF outreach efforts and spoken on behalf of the MMRF.
Mr. Giusti holds a Bachelor of Science degree from the Colorado School of Mines and an MBA from Harvard University.
Eugene P. Grisanti
Retired Chairman, President and CEO
International Flavors & Fragrances, Inc.
Eugene P. Grisanti is the former Chairman, President and CEO of International Flavors & Fragrances, the world’s largest flavor and fragrance company, a position he held for fifteen years, after serving as Senior Vice-President, General Counsel and other executive positions. He was a corporate attorney with the firm Fulton, Walter and Halley in New York City prior to joining IFF. Mr. Grisanti was elected to The Rockefeller University Board of Trustees in 1991, served as Chairman of The Rockefeller University Hospital Committee, and was elected Trustee Emeritus in 2000. Mr. Grisanti is Managing Director of The Metropolitan Opera, Vice-Chairman of The New York Botanical Garden, Chairman Emeritus of The New York City Ballet, and Director Emeritus of Lincoln Center for the Performing Arts. He is also a member of the Boards of the Ambrose Monell Foundation and the G. Unger Vetlesen Foundation. Eugene Grisanti received an A.B. from Holy Cross College, an LL.B. cum laude from Boston University, and an LL.M. from Harvard Law School.
David L. Lucchino
Co-Founder, President and Chief Executive Officer
David is the Co-founder, President and Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience and has played an integral role in launching, building and operating many successful companies in the life sciences and other innovation sectors. Previously, David was the President and Chief Executive Officer of Entrega Bio, a PureTech Health company developing an innovative capsule technology to make injectable substances available orally.
David’s first MIT-based startup was Semprus BioSciences, a biomedical company that went from business concept, to FDA 510(k) clearance and CE Mark approval, to major acquisition in five years. Semprus won the MIT $100K Entrepreneurial Competition for its business plan to develop a novel platform technology for reducing complications associated with long-term medical device implants, such as thrombosis and microbial adhesion. David subsequently led Semprus’ closing on several large financings before the company was acquired by Teleflex in 2012. Prior to Semprus, David was a Senior Executive at the leading venture capital firm, Polaris Partners, where he was responsible for deal-sourcing and originating and the execution of Polaris’ investment in Athletes Performance, a leading training facility for NFL, MLB, NHL and NBA professional athletes.
David launched his career in the life sciences by co-founding LaunchCyte, an investment firm specialized in commercializing biomedical intellectual property, and was instrumental in launching six companies from Carnegie-Mellon University and the University of Pennsylvania, among others. David currently serves as Vice Chairman of the Board of Directors of MassBio. He serves as a trustee and Chair of the Audit Committee of Mt. Auburn Hospital, a Harvard Medical School facility, and holds a Board position with the Multiple Myeloma Research Foundation. David is on the advisory council for the National Outdoor Leadership School (NOLS) where he was part of an expedition that summited Denali, North America’s high point. David earned an MBA at the MIT Sloan School of Management as an Alfred P. Sloan Fellow, an M.S. from Syracuse University and a B.A. from Denison University.
W. Dana LaForge
Brera Capital Partners, LLC
Dana LaForge is a Partner at Brera Capital Partners, a private equity fund, and the Founder and Managing Partner of Colonnade Financial Group, a private equity services firm. Prior to Brera and Colonnade, Dana was head of Financial Institutions Investment Banking and Chief of Staff of Banking and Capital Markets at Deutsche Bank and its predecessor companies. Earlier in his career, he was a bond trader and founded the Mortgage Finance Group. Dana has served on numerous portfolio company boards and is the Chairman of GAB Robins NA. He was one of the earliest Directors of the Multiple Myeloma Research Foundation joining the Board in 1999 and helping guide the Foundation from start up through today serving as the organization’s only Chairman since being elected in 2003. Dana earned a BS from Washington and Lee University and an MBA from Harvard Business School. He lives in New York City with his wife, Kathleen McCabe and their two daughters.
Joel S. Marcus
Chairman, Chief Executive Officer and Founder
Alexandria Real Estate Equities, Inc.
Joel S. Marcus has served as Chairman of the Board of Directors since May 2007, Chief Executive Officer since March 1997, President since February 2009, and a director since the Company’s inception in 1994. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011. From 1986 to 1994, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. From 1984 to 1994, he also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture which financed the development of, and owned patents to, two multi-billion dollar genetically engineered biopharmaceutical products. Mr. Marcus was formerly a practicing certified public accountant and tax manager with Arthur Young & Co. specializing in the financing and taxation of real estate and real estate investment trusts (REITs). He received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles. Mr. Marcus serves on the boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Foundation for the National Institutes of Health (FNIH), Intra-Cellular Therapies, Inc., Multiple Myeloma Research Foundation (MMRF), and the Partnership for New York City. Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles – Real Estate).
Mr. McDougall is Partner at PricewaterhouseCoopers Health Sciences Practice, where he provides services to academic medical centers, bioscience companies, pharmaceutical companies, research universities, colleges, health systems, and other research organizations. His practice provides a broad range of research business and compliance services, including strategic and business planning, financial analysis, research compliance, clinical research operations improvement, and information systems implementation services. In addition, his practice provides support services to the entire research continuum, from grant-funded basic science research, to translational research and clinical trials, including a dedicated group focusing on Clinical Research Consulting services.
William S. McKiernan
Former Chair and CEO
William McKiernan is the Chairman and Chief Executive Officer of CyberSource Corporation. Prior to founding CyberSource, Mr. McKiernan was President and Chief Operating Officer of McAfee Associates, now Network Associates; Mr. McKiernan held this position during the company’s initial public offering. Before joining McAfee, Mr. McKiernan was Vice President of Princeton Venture Research, Inc. and held management positions at ROLM/IBM. In addition to serving on the Board of Directors of the MMRF, Mr. McKiernan is the West Coast Chairman of the Boston College Technology Council. Mr. McKiernan holds a Bachelor of Science from Boston College and an MBA from Harvard Business School.
David R. Parkinson, MD
Chairman of the Clinical Advisory Board
From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based venture-financed biotechnology company developing technologies to enable personalized medicine and more efficient drug development in cancer and autoimmune diseases. Before joining Nodality, Dr. Parkinson was Senior Vice President, Oncology R&D, at Biogen Idec, overseeing oncology discovery research efforts and the development of the oncology pipeline. Previously he had served tenures as Vice President and Head of the Oncology Therapeutic Area at Amgen and Vice President and Head of Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec®, Femara®, Zometa®, Kepivance®, and Vectibix®. He received his M.D. from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training at McGill University and at New England Medical Center. Dr. Parkinson has authored more than 100 peer-reviewed scientific papers, and is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee as well as a recipient of the FDA’s Cody Medal.
Marie Pinizzotto, MD
President and CEO
Carol A. Ammon Foundation
Marie Pinizzotto, M.D., MBA, is currently the president and CEO of the Carol A. Ammon Foundation, a foundation focused on health care, education and children with disabilities. She was also the president of Drug Safety Solutions, L.L.C., a Pharmacovigilance and Risk Management consulting company whose main focus is pharmacovigilance and risk management for narcotics and other high risk drugs. Prior to starting her consulting firm she worked at Endo Pharmaceuticals Inc. where she was Senior Director of the Global Safety and Pharmacovigilance department. In this role she was responsible for pharmacovigilance of all Endo products, investigational as well as marketed. Marie was responsible for the safety components in following disciplines as well; Clinical Research, Medical Affairs and Clinical Education and Development. In addition, she led the Risk Management Team and was responsible for the creation and implementation of Endo’s risk management programs.
Before working at Endo, she was a Senior Director of Report Evaluation and Safety Surveillance for the Women’s Health Division and Consumer Products at Wyeth. In the Women’s health arena she was responsible for the development of the risk management and Pharmacovigilance plans for hormone replacement products. She also participated and chaired safety reviews of adverse events from clinical trials as well as marketed products.
Dr. Pinizzotto received her B.S in Chemistry, magna cum laude, from the University of Pittsburgh, Pittsburgh Pennsylvania and her medical degree from Jefferson Medical College in Philadelphia. She completed her residency at The Medical Center of Delaware, where she practiced obstetrics and gynecology for nine years. She still maintains privileges at the hospital. Most recently, Dr. Pinizzotto earned her MBA at the University of Delaware where she maintained a 4.0 GPA.
Currently Dr. Pinizzotto is a trustee of Christiana Care Hospital and a member of the Quality and Safety Committee. She is the named Chair, The Marie E. Pinizzotto, MD Chair of Academic Affairs, at Eisenhower Medical Center, Rancho Mirage, California. Dr. Pinizzotto sits on the boards of the following non-profit organizations: The Pregnancy Foundation, The Carol A. Ammon Foundation, which she is President and CEO. In additions she participates on the following two advisory boards: Scientific steering committee on Personalized Medicine for the Multiple Myeloma Research Foundation and Pediatric Disease Research for The Mario Batali Foundation. In addition she has been on the board for SOAR and Synova Pharmaceutical. She is also currently volunteering her time with Eisenhower Medical in Rancho Mirage, California as they embark on the development of a medical residency program and being considered as a trustee for the institution.
Fox Rothschild LLP
Michael Reinert is a leading music industry attorney who most recently served as Executive Vice President of Business & Legal Affairs for the Universal Motown Republic Group, a division of UMG Recordings, Inc. In that position, he had the pleasure of working with great talent such as Stevie Wonder, Elton John, Taylor Swift, Amy Winehouse, Lil Wayne, Nelly, Jack Johnson and many other platinum selling acts. Prior to joining Universal ten years ago, Michael was the Vice President of Business & Legal Affairs for PolyGram Records, handling those duties for the legendary Verve Records label and Mercury Nashville Records where he worked with the likes of Herbie Hancock and Shania Twain. Michael started his career in private practice representing many artists, producers and writers before joining the corporate ranks. Michael was an Adjunct Professor of Law at his alma mater, The Benjamin Cardozo School of Law of Yeshiva University, for ten years teaching Contract Drafting and Negotiation in the Music Industry. He has been a contributing editor to the Practicing Law Institute volumes on the same subject and continues to lecture at various schools and seminars around the country. He currently serves as the Chairman of the Entertainment Law Initiative of the Grammy Foundation, a division of the National Academy of Recording Arts and Sciences, which focuses on legal education programs for aspiring entertainment attorneys. Michael attended the Horace Mann School for Boys in Riverdale and Tulane University in New Orleans, a place he considers his second home. He lives in Manhattan with his wife of 30 years, Karen. They have a daughter and two beautiful grandchildren.
CEO and Founder
Rodger Riney grew up in Kirkwood, Missouri, and graduated from the University of Missouri with a Civil Engineering degree and an MBA. In 1969, he joined Edward D. Jones & Co. in Saint Louis and later became a partner. In 1980, he left to enter the relatively new discount brokerage industry by starting Scottrade. Over the years, Scottrade has evolved into an online brokerage and bank supporting its three million clients through 500 branch offices nationwide.
Throughout its history, Scottrade has built its success on a foundation of doing what’s right for its clients, with the mission to improve lives by helping people overcome the barriers to financial success. In the fall of 2016, Scottrade reached a definitive agreement to be acquired by TD Ameritrade.
Rodger has twice been named a regional finalist for Ernst & Young’s Financial Services Entrepreneur of the year, winning it in 2000 and becoming a national finalist for that honor in 2008.
In September 2015 Rodger was diagnosed with Multiple Myeloma and underwent a stem cell transplant.
Rodger is on the Board of the Saint Louis Chapter of the Alzheimer’s Association, the Governing Board of the Concordance Academy of Leadership and the Civic Board of the Salvation Army – Midland Division.
Steven Shak, MD
Co-Founder, Chief Scientific Officer
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as the Co-Founder, Chief Scientific Officer since 2012 and was the Chief Medical Officer from 2000 – 2013. Under Steve’s leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in Discovery Research and Medical Affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco.
Chief Financial Officer
Meryl Zausner is the Chief Financial Officer of Novartis Corporation and a member of the company’s Executive Committee. In this position, Ms. Zausner oversees Investor Relations, Controlling, Treasury, Cash Management, Tax and Risk Management across all of the Novartis divisions based in the US, as well as the financial management of the Novartis benefit plans.
Ms. Zausner has worked in the Consumer Products and Pharmaceutical industries for 28 years. Previously, she was Vice President and CFO of Novartis Oncology. In addition to her responsibilities as CFO, Ms. Zausner chaired the Novartis Pharmaceuticals 2006 & 2007 Global Diversity Council, of which she was a founding member. She was also a founding member of the U.S. EWIN (Empowering Women to Impact Novartis) Initiative now with over 1,500 members. In 2007, she was named (HBA) Healthcare Businesswomen Association’s Woman of the Year.
Before joining Novartis, Ms. Zausner held a variety of positions with the Colgate Palmolive Company and spent 3 years working in Public Accounting. She has degrees in Economics and Accounting from the University at Albany as well as her CPA in New York.
She is a member of the HBA Advisory Board, Corporate Council member of Deirdre House, which is an advocacy center for child victims of abuse or neglect, member of the Audit and Finance Subcommittee of PhRMA, Gilda’s Club 2009 Red Door Honoree and Board member of the T.J. Martell Foundation for Cancer Research.